MedCompanion

Chlamydia pneumoniae (Chlamydophila pneumoniae)

C. pneumoniae

Morphology: Obligate intracellular bacterium; biphasic life cycle (infectious elementary body / replicative reticulate body). No peptidoglycan — β-lactams inactive.

Atypical

Typical drugs

  1. #1AzithromycinFirst-line; same regimen as Mycoplasma.
  2. #2DoxycyclineEqually effective.
  3. #3LevofloxacinRespiratory FQ as monotherapy in CAP.
  4. #4Moxifloxacin

Empiric therapy when resistant

Resistance not clinically significant. Macrolide / tetracycline / respiratory FQ remain reliably active.

Resistance notes

Clinically meaningful resistance not described. β-lactams intrinsically inactive (no peptidoglycan).

Common syndromes

Pearls

Mild self-limited CAP in young adults, often with concurrent pharyngitis (more prominent than in Mycoplasma) and laryngitis. Longer incubation (3–4 weeks) than Mycoplasma. Often biphasic (URI prodrome → pneumonia 1–3 weeks later). Possible association with chronic conditions (atherosclerosis, asthma exacerbation) — controversial. Less severe than Mycoplasma; rarely requires hospitalization in healthy hosts.

References

  • IDSA/ATS Community-Acquired Pneumonia in Adults (2019)